A consensus statement developed by the Pan American League of Associations for Rheumatology (PANLAR) regarding biosimilars warned against the use of so-called "biomimics," or copy biologics.
A consensus statement developed by the Pan American League of Associations for Rheumatology (PANLAR) regarding biosimilars warned against the use of so-called biomimics, or copy biologics.
These products are local copies of approved biologic drugs that received approval without adhering to the international standards for evaluation and approval of biosimilars; the statement said such copies of etanercept and rituximab are available in some Asian and Latin American countries.
If these copies are to be sold, the statement said, they must first be evaluated and approved by a regulatory agency according to guidelines developed by the World Health Organization for new biologics and biosimilars.
The statement was developed through a literature review and a consensus was reached when there was agreement among 80% or more of the panel members. The review included 108 articles, which were classified into the following topics: extrapolation of indications, safety, regulation, interchangeability, pharmacovigilance, immunogenicity, and pharmacoeconomic.
Besides the warning about biomimics, the statement noted the following:
However, no consensus was achieved regarding extrapolation of indications, or about automatic substitution at the pharmacy counter without the permission of the provider.
Among the questions that must be settled, the statement said, are what would be required to designate a drug as interchangeable and how many switches between reference products and biosimilars would be needed in a clinical trial.
Reference
Kowalski, SC, Benavides, JA, Roa, PAB et al. PANLAR Consensus Statement on Biosimilars. Clin Rheumatol. 2019;38(5):1485-1496. doi: 10.1007/s10067-019-04496-3.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.